格列吡嗪

ɡé liè bǐ qín
  • Glipizide
格列吡嗪格列吡嗪
  1. 结果2型糖尿病患者血浆脂过氧化物水平和TNFα水平高于对照组,格列吡嗪控释片能使之降低至对照组相似的水平。

    Results Plasma lipid peroxide and tumor necrosis factor alpha levels were enhanced in type 2 diabetes mellitus patients , and glipizide GITS administration totally reversed these abnormalities .

  2. 目的:探讨格列吡嗪(Gli)及二甲双胍(Met)对2型糖尿病患者血清胰岛素样生长因子结合蛋白(IGFBP)-1影响。

    AIM : To study the effects of glipizide ( Gli ) and metformin ( Met ) on fast serum insulin like growth factor binding proteins 1 ( IGFBP 1 ) level in patients wiht type 2 diabetes mellitus .

  3. 血浆中格列吡嗪的HPLC测定

    HPLC determination of glipizide in plasma

  4. 方法:TLC法按中国药典2000年版格列吡嗪片有关物质检查薄层色谱条件;

    Methods : The TLC was concordant with the method described in Chinese Pharmacopoeia 2000 ;

  5. 结果格列吡嗪控释片每日服用1次的降糖效果与格列吡嗪速释片每日服用3次的降糖效果相同,控释片组胰岛素和C肽水平较低。

    Results controlled-release formula of glipizide once daily and immediate release glipizide 3 times per day showed a similar effect on glucose level , but the former did not increase insulin and C-peptide level .

  6. HPLC-MS研究格列吡嗪片人体药动学和生物等效性

    Study on Pharmacokinetics and Bioequivalence of Glipizide Tablets by HPLC-MS in Healthy Volunteers

  7. HPLC-MS测定人血浆中格列吡嗪及其药动学研究

    Determination of Glipizide in Plasma by HPLC-MS and Study on Its Pharmacokinetics in Healthy Subjects

  8. 结论格列吡嗪(2.95±0.6)h血药浓度达高峰,峰浓度为(456±60)ng/ml。

    Conclusion The plasma concentration of glipizide capsule attach peak in ( 2.95 ± 0 . 6 ) h , its peak concentration is ( 456 ± 60 ) ng / ml.

  9. 目的探讨临床常用的口服降糖药物格列吡嗪及二甲双胍和对Ⅱ型糖尿病人血清胰岛素样生长因子1,2(IGF1,2)的影响。

    Aim To study the effects of glipizide and metformin on the serum IGF_1 , IGF_2 in patients with type ⅱ diabetes mellitus ;

  10. 研究了羟丙甲纤维素(HPMC)水凝胶型格列吡嗪缓释片的制备及其释药特性。

    Glipizide hydrophilic gel tablets containing hydroxypropylmethyl-cellulos ( HPMC ) were prepared , and their drug release characteristic was also evaluated .

  11. 通过对格列吡嗪胶囊溶出度两种测定方法比较表明:HPLC法和UV法测定其溶出度结果:两者相差约10%,应以HPLC法测定为好。

    Through the comparison between two methods for determination the dissolution of Glipizide Capsules , the results showed : that HPLC method was better than UV method , and the variance . between two methods was about 10 %

  12. 目的探讨格列吡嗪治疗对2型糖尿病病人血清胰岛素样生长因子(IGF)及其结合蛋白(IGFBP)的影响。

    Objectives To study the effects of glipizide on the serum IGF-1 , IGF-2 , IGFBP-1 and IGFBP-3 in patients with type 2 diabetes mellitus .

  13. 方法单剂量给予国产的复方格列吡嗪片505mg(试验制剂)和格列吡嗪片5mg(参比制剂)、盐酸二甲双胍片500mg(参比制剂)。

    Methods A single oral dose ( 5 mg of Glipizide and 500 mg of Metformin hydrochloride ) was given to volunteers .

  14. 糖尿病组予格列吡嗪控释片5~10mg,每日1次,早餐前服用,疗程4wk。

    Patients in diabetes group received glipizide extended release 5-10 mg , qd , for 4 wk .

  15. 结果表明,采用醋酸纤维素为载体材料,选用合适的配方,可制得具有零级释药动力学的格列吡嗪控释微球制剂,并且该制剂可以根据需要的条件在12h或24h内释放完毕。

    The results suggest that the polymer matrix , function , and release media can affect the microsphere release properties . Zero-order release of glipizide in 12 h or 24 h could be achieved with cellulose acetate as the matrix in the optional formulation .

  16. 目的本文为了解决2型糖尿病中的多药治疗问题,用HPMC进行湿法制粒制备了复方二甲双胍格列吡嗪双层缓释片。

    Aim In this study , compound metformin / glipizide bilayer extended release tablets were formulated with hydroxypropyl methylcellulose ( HPMC ) by wet granulation technique in order to tackle the problems associated with the multidrug therapy of non-insulin dependent diabetes mellitus .

  17. 结果:3种格列吡嗪片在20min的溶出量均超过标示量的80%,但配对t检验显示T50、Td具有显著差异(P<0.01)。

    RESULTS : More than 80 % of the labeled amount of three kinds of glipizide tablet were dissolved in 20 minutes , but statistical analysis showed there were significant differences in T 50 , T d between the products from different factories ( P < 0.01 ) .

  18. 黄连素联合格列吡嗪对2型糖尿病治疗效果的研究

    Therapeutic Efficacy of Combined Berberine and Glipizide on Type 2 Diabetes

  19. 格列吡嗪缓释片的制备及其体外释放度考察

    Study on preparation and in-vitro release of glipizide sustained release tablets

  20. 格列吡嗪缓释微丸生产工艺改进研究

    Study on the Improvement of Process Technology of Glipizide Sustained-Release Pellets

  21. 格列吡嗪控释微球的制备及体外释药性质

    Preparation and in vitro release of glipizide loaded controlled release microspheres

  22. 格列吡嗪片人体的药代动力学及生物等效性评价

    Evaluation of Pharmacokinetics and Bioequivalence of Glipizide Tables in Healthy Volunteers

  23. 格列吡嗪胶囊人体药动学及相对生物利用度的研究

    Study on the pharmacokinetics and relative bioavailability of glipizide in human

  24. 目的:考察格列吡嗪胶囊人体相对生物利用度及生物等效性。

    Objective To study the relative bioavailability and bioequiavailability of Glipizide capsule .

  25. 格列吡嗪控释片和格列美脲治疗2型糖尿病的对比研究

    Treatment for type 2 diabetic mellitus with Glipizide sustained-release tablet or Glimepiride

  26. 格列吡嗪胃肠道生物粘附缓释片的研制

    Preparation and Study of Glipizide Gastrointestinal Tract Bioadhesion Sustained-release Tablet

  27. 格列吡嗪控释片治疗2型糖尿病

    Efficacy of Controlled - Release Glipizide in Treatment of Type 2 Diabetes

  28. 两种测定格列吡嗪胶囊溶出度方法的比较

    The comparison between two methods for determination the dissolution of Glipizide Capsules

  29. 高效液相色谱法检测降糖中药制剂中违法添加的格列吡嗪

    Determination of Glipizide Mixed Illegally in Traditional Chinese Medicine Preparations by HPLC

  30. 格列吡嗪-β-环糊精包合物的制备及其理化性质考察

    Preparation and Physicochemical Properties of Glipizide - β - Cyclodextrin Inclusion Complex